Abbott Laboratories (ABT) Revenue (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Revenue data on file, last reported at $11.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 7.78% year-over-year to $11.2 billion; the trailing twelve-month figure through Mar 2026 stood at $45.1 billion (up 6.59% YoY), and the FY2025 full-year result was $44.3 billion, up 5.67% from the prior year.
• Revenue retreated to $11.2 billion in Q1 2026, from $11.5 billion in the prior quarter.
• In the past five years, Revenue ranged from a high of $11.9 billion in Q1 2022 to a low of $9.7 billion in Q1 2023.
• A 5-year average of $10.7 billion and a median of $10.4 billion in 2022 frame the typical range for Revenue.
• Across the five-year window, Revenue advanced 13.76% in 2022 and declined 18.06% in 2023, its largest moves.
• Tracing ABT's Revenue over 5 years: stood at $10.1 billion in 2022, then grew by 1.49% to $10.2 billion in 2023, then rose by 7.16% to $11.0 billion in 2024, then grew by 4.42% to $11.5 billion in 2025, then fell by 2.57% to $11.2 billion in 2026.
• Business Quant data shows ABT's Revenue at $11.2 billion in Q1 2026, $11.5 billion in Q4 2025, and $11.4 billion in Q3 2025.